Form 4: Galectin Therapeutics CEO Sells Shares Post-RSU Vesting

Galectin Therapeutics Inc. CEO Joel Lewis reported the vesting of 84,000 Restricted Stock Units and subsequent sales of an equal number of common shares under a pre-arranged 10b5-1 plan.

Summary

• Joel Lewis, President and CEO, and Director of Galectin Therapeutics Inc. (GALT), reported transactions involving the company's common stock.
• On January 2, 2026, Mr. Lewis acquired 84,000 shares of common stock at a price of $0, resulting from the vesting of Restricted Stock Units (RSUs).
• Concurrently, and as part of a Rule 10b5-1 plan adopted on April 17, 2025, Mr. Lewis sold a total of 84,000 shares of common stock across three separate transactions.
• The sales occurred on January 2, 2026 (18,571 shares at a weighted average price of $4.1968), January 5, 2026 (27,731 shares at a weighted average price of $3.9069), and January 6, 2026 (37,698 shares at a weighted average price of $3.5772).
• Following these transactions, Mr. Lewis directly beneficially owns 832,592 shares of common stock.
• He also indirectly holds 2,000 shares as a custodian for a minor child under the Uniform Transfer to Minors Act, disclaiming beneficial ownership of these shares.

Sentiment

Score: 6

Explanation: The vesting of RSUs is a positive for the executive, reflecting earned compensation. The subsequent sales, while reducing direct ownership, were conducted under a pre-arranged 10b5-1 plan, which generally mitigates negative sentiment associated with insider selling as it implies planned liquidity rather than a reaction to negative company news. The declining sale prices are a minor negative, but the overall context of a 10b5-1 plan makes the sentiment neutral.

Positives

• Vesting of 84,000 Restricted Stock Units indicates the fulfillment of long-term incentive compensation for the CEO.
• The sales were conducted under a pre-arranged Rule 10b5-1 plan, which provides an affirmative defense against insider trading allegations, suggesting planned liquidity rather than opportunistic selling.

Negatives

• The CEO sold a significant number of shares (84,000) over a short period, which could be interpreted as a reduction in direct exposure to the company's stock.
• The weighted average sale prices declined over the three transaction dates, from $4.1968 to $3.5772, potentially indicating a downward trend in the stock price during the selling period.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports past insider transactions.

Management Comments

• The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
• Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.
• The Reporting Person disclaims beneficial ownership of these securities [2,000 shares held as custodian], and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.

Industry Context

This filing is a standard insider transaction report and does not provide information to analyze broader industry trends or competitive landscape. It reflects an individual executive's stock activity rather than company-wide strategic developments.

Comparison to Industry Standards

• This Form 4 filing reports routine insider transactions (RSU vesting and subsequent sales under a 10b5-1 plan). Such transactions are common among executives in publicly traded companies across various industries, including biotechnology, as part of their compensation and personal financial planning.
• The use of a Rule 10b5-1 plan is considered a best practice for executives to sell shares in a pre-scheduled manner, mitigating concerns about trading on material non-public information. This aligns with corporate governance standards seen in companies like Pfizer, Amgen, or Gilead Sciences, where executives frequently utilize such plans for stock sales.
• The specific volume of shares sold (84,000) relative to the executive's remaining direct beneficial ownership (832,592 shares) represents approximately 9.2% of the post-vesting direct holdings, which is not an unusually high percentage for an executive diversifying their portfolio or covering tax obligations associated with RSU vesting.

Related Party Transactions

• The filing reports transactions by Joel Lewis, President and CEO, and Director, which are by definition related party transactions (insider transactions). No other related party dealings are disclosed.

Stakeholder Impact

• Shareholders: May view the insider selling, even under a 10b5-1 plan, with some caution, as it reduces the CEO's direct stake. However, the vesting of RSUs is a routine compensation event. The declining sale prices might reflect broader market sentiment for GALT stock.

Key Dates

Keywords

Galectin Therapeutics Inc., GALT, Joel Lewis, Insider Trading, Form 4, SEC Filing, Stock Sales, Restricted Stock Units, 10b5-1 Plan, CEO, Beneficial Ownership